Explore

Trendline Trendline
Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings
Trendline Trendline
DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead
Trendline Trendline
IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026

IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026

IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments

Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments

Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments
Trendline Trendline
Madrigal Pharmaceuticals Expands siRNA Portfolio with $1B Arrowhead Deal

Madrigal Pharmaceuticals Expands siRNA Portfolio with $1B Arrowhead Deal

Madrigal Pharmaceuticals Expands siRNA Portfolio with $1B Arrowhead Deal
Trendline Trendline
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request

Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request

Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request
Trendline Trendline
Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement

Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement

Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement